BIIB vs. HALO: Biogen vs. Halozyme Therapeutics Stock Comparison
How do Biogen (BIIB) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Biogen (BIIB) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BIIB | HALO |
|---|---|---|
| Name | Biogen Inc. | Halozyme Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 36.71 billion USD | 11.81 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | September 17, 1991 | March 16, 2004 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIIB | HALO |
|---|---|---|
| Total Return (1Y) | 65.44% | 50.94% |
| Total Return (3Y, Annualized) | 4.62% | 41.08% |
| Total Return (5Y, Annualized) | -0.96% | 21.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIIB | HALO |
|---|---|---|
| Volatility (1Y, Annualized) | 34.58% | 41.19% |
| Beta (5Y) | 0.08 | 0.96 |
| Max Drawdown (5Y) | -64.35% | -49.06% |
| Avg. Volume (3M) | 1.05M | 2.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIIB | HALO |
|---|---|---|
| Sharpe Ratio (1Y) | 1.77 | 1.13 |
| Sortino Ratio (1Y) | 2.77 | 1.78 |
Profitability
ROE (TTM)
Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Biogen (BIIB) at 1.87%, which is closer to a typical peer reading.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.87%
- Max
- 109.18%
- Q3
- 6.23%
- BIIB
- 1.87%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.38%
- Max
- 18.05%
- Q3
- 4.78%
- BIIB
- 3.38%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Biogen (BIIB) at 24.12% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.12%
- Max
- 83.12%
- BIIB
- 24.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIIB | HALO |
|---|---|---|
| ROE (TTM) | 1.87% | 216.38% |
| ROA (TTM) | 4.94% | 22.42% |
| Net Margin (TTM) | 3.38% | 26.93% |
| Operating Margin (TTM) | 24.12% | 59.84% |
| Gross Margin (TTM) | 75.77% | 77.74% |
Growth
Revenue Growth
Both Biogen (BIIB) at 2.22% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Biogen (BIIB) at -21.38% and Halozyme Therapeutics (HALO) at -25.36% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | BIIB | HALO |
|---|---|---|
| Revenue Growth (YoY) | 2.22% | 37.55% |
| Revenue Growth (3Y CAGR) | -0.94% | 28.38% |
| EPS Growth (YoY) | -21.38% | -25.36% |
| EPS Growth (3Y CAGR) | -25.04% | 21.14% |
Financial Strength
Current Ratio (MRQ)
Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BIIB
- 1.95
- Min
- 0.10
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Biogen (BIIB) carries debt-to-equity ratio of 0.41 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41
- Max
- 1.42
- Q3
- 0.65
- BIIB
- 0.41
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
Financial Strength Metrics
| Metric | BIIB | HALO |
|---|---|---|
| Current Ratio (MRQ) | 1.95 | 3.88 |
| Debt / Equity (MRQ) | 0.41 | -- |
| Net Debt / EBITDA | 1.97 | 1.90 |
Dividends
Dividend Yield (TTM)
Neither Biogen (BIIB) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Biogen (BIIB) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIIB | HALO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.51
- BIIB
- 107.51
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Biogen (BIIB) at 3.57 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.57
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIIB
- 3.57
- Q1
- 3.01
- Min
- 0.01
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Biogen (BIIB) reports 1.94, ranking against industry peers normally.
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BIIB
- 1.94
- Q1
- 1.69
- Min
- -5.59
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
Valuation Metrics
| Metric | BIIB | HALO |
|---|---|---|
| P/E Ratio (TTM) | 107.51 | 25.91 |
| P/S Ratio (TTM) | 3.57 | 6.55 |
| P/B Ratio (MRQ) | 1.94 | -213.67 |
| Free Cash Flow Yield (TTM) | 2.20% | 3.48% |